Last reviewed · How we verify
NCT03307811
Endoscopic Ultrasound Guided Liver Biopsy
NA trial testing 22 gauge needle liver biopsy in Hepatic Cancer in 40 participants. Completed in 1 October 2018.
19 June 2018
Quick facts
| Lead sponsor | AdventHealth |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 40 |
| Start date | 1 August 2017 |
| Primary completion | 19 June 2018 |
| Estimated completion | 1 October 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 22 gauge needle liver biopsy
Conditions studied
- Hepatic Cancer — all drugs for Hepatic Cancer →
- Hepatic Neoplasm — all drugs for Hepatic Neoplasm →
- Hepatic Carcinoma — all drugs for Hepatic Carcinoma →
Sponsor
AdventHealth — full company profile →
Who can join
19 and older, any sex, with Hepatic Cancer or Hepatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective study to determine the optimal technique for obtaining liver tissue with a smaller caliber (22 gauge) needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 22 g Fine Needle Biopsy needle for liver biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03307811
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatic Cancer
Currently open trials in the same condition.
- NCT07034950 — Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation · Phase 1, PHASE2 · active not recruiting
- NCT06492408 — Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. · Phase 2 · recruiting
- NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
- NCT05957822 — Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery · Phase 4 · recruiting
Other AdventHealth trials
Trials by the same sponsor.
- NCT07359352 — Surgical Care And Recovery With Laser Evaluation Trial (SCARLET) · NA · not yet recruiting
- NCT07472127 — Professional Readiness Through Emotional Preparedness (PREP) · NA · not yet recruiting
- NCT07357376 — Evaluating Suzetrigine for Pain Control Following TKA · Phase 3 · not yet recruiting
- NCT07298018 — A Pilot Study of RISE for Nurse Managers Retreat · NA · recruiting
- NCT07081542 — Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03307811 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AdventHealth
- Last refreshed: 11 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03307811.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing